178 results on '"Iwasawa, Yoshikazu"'
Search Results
2. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
3. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
4. Supplementary Figure 3 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
5. Supplementary Figure 1 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
6. Supplementary Figure 4 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
7. Supplementary Figure 2 from Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
8. Supplementary Figure 1 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
9. Data from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
10. Supplementary Table 1 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
11. Supplementary Figure 2 from MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
12. Establishment of a human hepatocellular cell line capable of maintaining long-term replication of hepatitis B virus
13. Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation
14. Abstract P06-02: Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations
15. Efficient and practical asymmetric synthesis of 1- tert-butyl 3-methyl (3 R,4 R)-4-(2-oxo-2,3-dihydro-1 H-benzimidazol-1-yl)piperidine-1,3-dicarboxylate, a useful intermediate for the synthesis of nociceptin antagonists
16. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
17. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo
18. Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
19. Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor
20. Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor
21. Synthesis of J-113397, the first potent and selective ORL1 antagonist
22. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist
23. Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth
24. TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
25. Abstract A169: Combination of TPC-144, a reversible LSD1 inhibitor, and a hypomethylating agent resulted in synergistic antitumor efficacy in preclinical models of AML
26. Abstract B180: TAS-115 attenuates tumor-associated macrophages and enhances sensitivity to anti-PD-1 monoclonal antibody in syngeneic mouse tumors
27. Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
28. Abstract B136: NEDD8-activating enzyme inhibitor TAS4464 inhibits tumor growth in endometrial cancer mouse model accompanied by DNA damage response
29. The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
30. Abstract 3777: TAS4464, a novel and highly potent NEDD8 activating enzyme (NAE) inhibitor, causes apoptosis of sarcomas via cell cycle dysregulation
31. Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity
32. Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity.
33. Abstract C178: TAS4464, a novel NEDD8 activating enzyme inhibitor, potently induces cell death via both intrinsic and extrinsic apoptotic pathways in acute myeloid leukemia
34. Abstract C104: TAS-121, a highly potent and mutant-specific EGFR inhibitor, modulates the immune system, resulting in anti-tumor immune responses
35. Abstract C177: TAS4464, a novel and highly potent inhibitor of NEDD8 activating enzyme, overcomes insensitivity to BTK, PI3Kδ, and IRAK4 inhibitors in activated B-cell like diffuse large B-cell lymphoma via inactivation of the NF-κB pathway
36. Abstract PR09: TAS3681, a new type androgen receptor antagonist, suppresses ligand-independent AR activation through its AR downregulation activity
37. Abstract C176: TAS4464, a novel, highly potent, and selective inhibitor of NEDD8 activating enzyme demonstrates sustained target inhibition and antitumor activity in a preclinical model
38. Abstract 1730: TAS4464, a novel highly potent NEDD8 activating enzyme inhibitor, demonstrates antitumor activity in multiple myeloma through the inactivation of NF-κB pathways
39. TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption.
40. 看護介入と作業療法介入の連携による効果 -セルフケア欠如のある妄想性障害の患者ケアを通して
41. TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-κB Pathway
42. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors
43. Abstract C111:In vitrocharacterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI.
44. Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.
45. Identification of novel benzimidazole series of potent and selective ORL1 antagonists
46. ChemInform Abstract: Discovery of the First Potent and Selective Small Molecule Opioid Receptor-Like (ORL1) Antagonist: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl] -3-ethyl-1,3-diyhdro-2H-benzimidazol-2-one (J-113397).
47. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
48. ChemInform Abstract: Synthesis of J-113397, the First Potent and Selective ORL1 Antagonist.
49. Structures of the PKC-ι kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533–551 in the C-terminal tail and their roles in ATP binding
50. Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.